ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interleukins (IL)"

  • Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting

    COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic

    Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland

    Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…
  • Abstract Number: 1168 • 2013 ACR/ARHP Annual Meeting

    Innate Immune Cell Production Of Interleukin-12 Drives CpG-Induced Macrophage Activation Syndrome

    Lehn K. Weaver1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pediatrics/Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Hemophagocytic syndromes are caused by an uncontrolled systemic inflammatory response resulting in cytopenias, multisystem organ failure, and rapid death, often despite aggressive therapy. Macrophage…
  • Abstract Number: 951 • 2013 ACR/ARHP Annual Meeting

    The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF

    Christine Huppertz, Marija Curcic Djuric, Robert Hennze and Frank Kolbinger, Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland

    Background/Purpose: Fibroblast-like synoviocytes (FLS) are targets of the pro-inflammatory IL-17 cytokines and a major source of inflammatory mediators in the inflamed synovium in rheumatoid arthritis…
  • Abstract Number: 939 • 2013 ACR/ARHP Annual Meeting

    Reduction Of Circulating Blood Neutrophils In Mice By Anti-IL-6R Alpha Monoclonal Antibody is Not Due To Apoptosis Or Blockade Of Neutrophil Differentiation

    Ludmila Kelly, Vilma Decman and Dimitris Skokos, Research, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

    Background/Purpose: Blockade of IL-6/IL-6Rα signaling is associated with a reduction of circulating neutrophils in the blood of patients treated with anti-IL-6Rα mAb but the mechanism…
  • Abstract Number: 931 • 2013 ACR/ARHP Annual Meeting

    Effect Of Neutralizing IL-17A and IL-17F Antibodies On Host Resistance To Acute Mycobacterium Tuberculosis Infection In Mice In Comparison With Neutralizing TNF-α Treatment

    Michael Kammüller1, Franco Di Padova2, Christian Antoni3, Salah-Dine Chibout4, Timothy Wright5, Marie-Laure Bourigault6, Noria Segueni6, Stephanie Rose6, Bernhard Ryffel6 and Valerie Quesniaux6, 1PCS - Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland, 2Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Novartis Institutes for Biomedical Research, Basel, Switzerland, 5Novartis Pharma AG, Basel, Switzerland, 6UMR7355 CNRS and University of Orleans, Orleans, France

    Background/Purpose: Antibodies targeting IL-17A or IL-17RA are in clinical trials for the treatment of several autoimmune diseases.  However, these therapies, by blocking critical mediators of…
  • Abstract Number: 940 • 2013 ACR/ARHP Annual Meeting

    Novel Function Of Soluble Interleukin-6 Receptor As An Antagonist Of Interleukin-27-Mediated Anti-Inflammatory Responses

    Misato Hashizume1, Keiko Esaki2, Keiko Yoshimoto3, Hideto Kameda3, Tsutomu Takeuchi3 and Yoshihiro Matsumoto1, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: The immunological roles of interleukin 27 (IL-27) have been reported in various rheumatic diseases, such as rheumatoid arthritis (RA), lupus, systemic sclerosis and psoriasis.…
  • Abstract Number: 943 • 2013 ACR/ARHP Annual Meeting

    Synergism Between Granulocyte-Macrophage Colony Stimulating Factor and Interleukin-17 Causes Joint Damage Via The Production Of Interleukin-23, Receptor Activator Of NF-κB Ligand and S100A8

    Annemarie E.M. Van Nieuwenhuijze1, Fons A.J. Van de Loo2, Birgitte Walgreen3, Miranda B. Bennink4, Monique M. Helsen3, Liduine Van den Bersselaar1, Ian P. Wicks5,6, Wim B. Van den Berg7 and Marije I. Koenders7, 1Rheumatology and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, Australia, 6Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, 7Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

    Background/Purpose: T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent…
  • Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting

    Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab

    Sebastian Kraus1, Matthias Englbrecht1, Juergen Rech2, Roland Kocijan1, Georg A. Schett1 and Stephanie Finzel1, 1Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…
  • Abstract Number: 948 • 2013 ACR/ARHP Annual Meeting

    Dual Neutralization Of TNF and IL-17 Provides Greater Efficacy In Collagen Induced Arthritis Through Regulation Of a Gene Transcription Program That Includes CXCL1 and CXCL5

    Carolyn Cuff1, Chung-Ming Hsieh2, Suzanne Mathieu3, Anwar Murtaza4, Margaret Hugunin3, Shaughn Bryant3, Robert O'brien3, Lisa Olson5 and Jeffrey Voss3, 1Immunology, AbbVie, Inc, Worcester, MA, 2Biologics, AbbVie Pharmaceuticals, Worcester, MA, 3Immunology, AbbVie Pharmaceuticals, Worcester, MA, 4Broad Institute, Cambridge, MA, 5AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: Dual neutralization of TNF and IL-17 is hypothesized to provide greater efficacy in rheumatoid arthritis (RA) and inflammatory diseases compared to either monotherapy as…
  • Abstract Number: 2695 • 2013 ACR/ARHP Annual Meeting

    Host Genetic Background Disrupts The Relationship Between Microbiota and Gut Mucosal Tolerance Leading To Spondyloarthritis and Ileitis After a Dectin-1 Trigger

    Linda Rehaume1, Stanislas Mondot2, Daniel Aguirre de Cárcer2, Jared Velasco1, Helen Benham1, Sumaira Hasnain3, Jaclyn Bowman1, Merja Ruutu1, Philip Hansbro4, Michael McGuckin3, Mark Morrison2 and Ranjeny Thomas1, 1University of Queensland Diamantina Institute, Brisbane, Australia, 2CSIRO Livestock Industries, Brisbane, Australia, 3Mater Medical Research Institute, Brisbane, Australia, 4Center for Asthma and Respiratory Disease and Hunter Medical Research Institute, Newcastle, Australia

    Background/Purpose: Chronic inflammatory diseases known as spondyloarthropathies (SpA) including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and arthritis associated with inflammatory bowel disease, collectively affect 3%…
  • Abstract Number: 918 • 2013 ACR/ARHP Annual Meeting

    Regulatory B Cells Suppress Skin Inflammation in a Murine Model of Psoriasis

    Koichi Yanaba1 and Shinichi Sato2, 1Dermatology, The University of Tokyo, Tokyo, Japan, 2Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Psoriasis is a cutaneous disorder characterized by widespread erythematous plaques with adherent scales. Recent studies have revealed that both T helper (Th) 17 and…
  • Abstract Number: 2500 • 2013 ACR/ARHP Annual Meeting

    Mast Cells Are a Major Source Of IL-17 In Synovium and Extra-Articular Tissues In Spondyloarthritis Related Diseases

    T. Noordenbos1, I. Gofita1, M. Alsina2, E.W.M. Vogels3, A. A. te Velde3, J. D. Cañete4, Dominique L. Baeten5 and N. Yeremenko1, 1Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, 2Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain, 3Tytgat Institute for Liver and Intestinal Research, Academic Medical Centre/University of Amsterdam, the Netherlands, Amsterdam, Netherlands, 4Rheumatology, Hospital Clinic, Barcelona, Spain, 5Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: IL-17 plays a key role in the pathogenesis of spondyloarthritis (SpA) as demonstrated by a recent proof-of-concept trial with the anti-IL17A mAb secukinumab. The…
  • Abstract Number: 823 • 2013 ACR/ARHP Annual Meeting

    Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages

    Christian Beyer1, Jürgen Beer1, Katrin Palumbo-Zerr1, Pawel Zerr1, Alfiya Distler1, Clara Dees1, Louis E. Munoz1, Gerhard Krönke1, Oliver Distler2, Steve Anderson3, Georg A. Schett4 and Joerg H. W. Distler1, 1Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Lexicon Pharmaceuticals Inc., The Woodlands, TX, 4Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Liver X receptors (LXRs) are orphan nuclear receptors with emerging roles in metabolic and autoimmune diseases. Here, we investigated the role of LXRs in…
  • Abstract Number: 2503 • 2013 ACR/ARHP Annual Meeting

    IL-17+ CD8+ T Cells Are Enriched In The Joints Of Patients With Psoriatic Arthritis and Correlate With Markers Of Disease Activity and Joint Damage Progression

    Bina Menon1,2, Nicola J. Gullick3, Hayley G. Evans4, Gina J. Walter4, Megha Rajasekhar4, Toby Garrood2, Leonie S. Taams4 and Bruce W. Kirkham2, 1Centre for Cellular and Molecular Biology of Inflammation, King's College London, London, United Kingdom, 2Rheumatology, Guy's and St. Thomas' Foundation Hospital NHS Trust, London, United Kingdom, 3Rheumatology, King's College Hospital Foundation NHS Trust, London, United Kingdom, 4Centre for Molecular and Cellular Biology of Inflammation, King's College London, London, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) have clear differences in clinical, radiological and genetic features, suggesting that the immunopathology of the conditions may…
  • Abstract Number: 595 • 2013 ACR/ARHP Annual Meeting

    Anemic Hypoxia Is Associated With Pulmonary Arterial Hypertension In Patients With Systemic Lupus Erythematosus

    Ki-Jo Kim1, In-Woon Baek2, Chong-Hyeun Yoon3, Jin-Jung Choi4, Wan-Uk Kim2 and Chul-Soo Cho5, 1Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, 2Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, 4Internal Medicine, CHA University Hospital, Seongnam, South Korea, 5Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious and often fatal complication of systemic lupus erythematosus (SLE), but its pathogenesis is still unclear. Hypoxia-induced pulmonary…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology